Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2004

Morley Stephen, MacDonald Gordon, Kirn David, Kaye Stan, Brown Robert, Soutar David

Abstract excerpt

PURPOSE: dl1520 (also known as Onyx-015) is an E1B-deleted adenovirus designed to selectively lyse p53-deficient cancer cells. Clinical trials involving patients with recurrent squamous cell carcinoma of the head and neck have shown clinical efficacy, but no direct evidence as to the tumor or p53 selectivity of the virus was demonstrated. We wanted to determine whether dl1520 is selective for survival and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Death

Share to Clinical Trials as Topic

Share to In Situ Hybridization

Share to In Situ Nick-End Labeling

Share to Mouth Neoplasms

Share to Viral Vaccines

Source

Identifiers

PMID: 15240522
DOI: 10.1158/1078-0432.CCR-03-0443

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma.PMID 15240522Read ↗

Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015).Semantic proximity Read ↗

Assessment of growth inhibition and morphological changes in in vitro and in vivo hepatocellular carcinoma models post treatment with dl1520 adenovirus.Semantic proximity Read ↗

In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy.Semantic proximity Read ↗

Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.Semantic proximity Read ↗

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.Semantic proximity Read ↗

Phase I Trial of Intraperitoneal Injection of the E1B-55-kd-Gene-Deleted Adenovirus ONYX-015 (dl1520) Given on Days 1 Through 5 Every 3 Weeks in Patients With Recurrent/Refractory Epithelial Ovarian CancerSemantic proximity Read ↗

Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?Semantic proximity Read ↗

A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.Semantic proximity Read ↗

Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells.Semantic proximity Read ↗

Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants.Semantic proximity Read ↗

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity.Semantic proximity Read ↗

Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.